FDA declines pediatric EUA for Ocugen's COVID vaccine Covaxin

1 minute read

Indian Health Minister Harsh Vardhan holds a dose of Bharat Biotech's COVID-19 vaccine called COVAXIN, during a vaccination campaign at All India Institute of Medical Sciences (AIIMS) hospital in New Delhi, India, January 16, 2021. REUTERS/Adnan Abidi/Files/File Photo

Register now for FREE unlimited access to Reuters.com

March 4 (Reuters) - Ocugen Inc (OCGN.O) said on Friday U.S. regulators have declined to issue an emergency use authorization (EUA) for Covaxin, the COVID-19 vaccine developed by its Indian partner Bharat Biotech, for use in individuals aged 2 to 18 years.

Shares of Ocugen slumped 30% premarket on the news.

Ocugen said it intends to continue working with the U.S. Food and Drug Administration to evaluate the process for getting an EUA for pediatric use of Covaxin.

Ocugen had entered into a deal with vaccine maker Bharat Biotech in late 2020, under which it would develop, supply, and commercialize Covaxin for the U.S. market. (https://reut.rs/35nVA1P)

Covaxin, which is not cleared for any age group in the United States, is one of the two most widely used COVID vaccines in India and also has an emergency use listing from the World Health Organization.

Register now for FREE unlimited access to Reuters.com
Reporting by Leroy Leo in Bengaluru; Editing by Aditya Soni and Shailesh Kuber

Our Standards: The Thomson Reuters Trust Principles.